What are the current treatment options available for hepatocellular carcinoma?
Multiple treatment options are available for HCC including curative resection, liver transplantation, radiofrequency ablation, trans-arterial chemoembolization, radioembolization and systemic targeted agent like sorafenib.
How treatable is hepatocellular carcinoma?
If caught early, it can sometimes be cured with surgery or transplant. In more advanced cases it can’t be cured, but treatment and support can help you live longer and better. It’s important to remember that you still have control over the decisions you make about your treatment and your life.
How do you manage hepatocellular carcinoma?
Early stage hepatocellular carcinoma is best managed by curative treatment, which includes resection, ablation, or transplantation. Patients with intermediate stage disease often receive locoregional treatment. Systemic treatment is reserved for patients with advanced disease.
Can immunotherapy cure HCC?
Current immunotherapy of HCC Results from several clinical trials demonstrate that immune-based therapy can improve outcomes for patients with HCC. In one large trial, 150 patients were randomized to receive either IL-2 and anti-CD3-activated PBMC or observation post curative resection.
How long can you live after TACE?
The median overall survival of all patients with TACE treatment was 8.7 months. However, elderly patients who received TACE treatment for HCC had a significantly higher overall median survival than young patients (14.0 months vs 8.1 months, P < .
Does TACE cure HCC?
TACE is a treatment, not a cure. Approximately 70 percent of the patients will see improvement in the liver and, depending on the type of liver cancer, it may improve survival rates and quality of life.
What is standard of care in HCC?
According to most international guidelines for the treatment of HCC, palliative transarterial chemoembolization (TACE) is the standard of care for patients without a curative treatment option, with liver-only disease, and without macrovascular invasion (BCLC stage B) [15].
Does immunotherapy shrink liver tumors?
For most liver cancer patients, immunotherapy does not produce effective results but new data suggests a revamped strategy can make unresponsive liver tumors highly responsive. In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.
How long does immunotherapy extend life?
Generally, at 2 years, if patients have done well on therapy, and you have 2 years of ongoing disease control, in most patients we are stopping at 2 years and then monitoring them.
What is the success rate of TACE?
How effective is TACE for HCC?
A more recent systematic review with data from more than 10,000 patients with HCC undergoing TACE found that the objective response was 52.5%, while overall survival was 70.3% at 1 year, 51.8% at 2 years, 40.4% at 3 years, and 32.4% at 5 years [21].